We are live on ! Find out more
MASS icon

908 Devices

10.56 USD
+0.41
4.04%
At close Updated Nov 6, 4:00 PM EST
Pre-market
After hours
10.35
-0.21
1.99%
1 day
4.04%
5 days
-6.96%
1 month
-14.36%
3 months
27.23%
6 months
31.02%
Year to date
107.47%
1 year
35.38%
5 years
-72.76%
10 years
-78.45%
 

About: 908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.

Employees: 172

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 35.7%
Neutral 57.1%
Negative 7.1%
Neutral
Business Wire
2 days ago
908 Devices to Participate in the Stifel 2026 Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced that management will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 4:00 p.m. ET. A live webcast of the fireside chat will be available in the “Investors” section of the company's website at: www.908devices.c.
908 Devices to Participate in the Stifel 2026 Healthcare Conference
Neutral
Seeking Alpha
7 days ago
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
Neutral
Business Wire
10 days ago
908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the third quarter 2026 before market open on Tuesday, November 10, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors”.
908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
Neutral
Business Wire
2 months ago
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
Positive
MarketBeat
2 months ago
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
Positive
MarketBeat
2 months ago
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
Positive
MarketBeat
2 months ago
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
Positive
Seeking Alpha
2 months ago
908 Devices Q2: Another Solid Report
908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
908 Devices Q2: Another Solid Report
Positive
Seeking Alpha
2 months ago
908 Devices: Mission Critical Devices Drive Growth
908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
908 Devices: Mission Critical Devices Drive Growth
Neutral
Business Wire
2 months ago
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The Company presentation is scheduled to begin at 9:55 a.m. CT / 10:55 a.m. ET. The presentation is.
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
Price charts implemented using Lightweight Charts™